


# TECHNOLOGY OFFER

## Epidermal growth factor-derived with antitumor activity (tEGFha)

The current treatments, against the epidermal growth factor (EGFR), have resistances, lack of specificity, limited efficacy, side effects and an increased cost, which limit their usage. The proposed solution, the derivative tEGFha, mimics the natural ligand, block its activation and inhibits the tumour growth. As a small protein, it is easy and economical to produce, enhancing the accessibility of the patients. Moreover, it can combine with chemotherapeutic agents or radioisotopes to better direct them to tumours and to increase the specificity. Other functions include the use of image techniques, to perform diagnosis and therapy simultaneously (theragnosis).



## COMPETITIVE ADVANTAGE

- Easy to conjugate with existing chemotherapeutic or radioactive agents.
- Personalization to improve its properties.
- Enhanced tissue diffusing ability.
- Lower immunogenic reactions compared with present treatments (antibodies anti-EGFR).
- Lower cost and easy to produce.

## OBJECTIVE MARKET

- Pharmaceutical companies.
- Research facilities and hospitals specialized in oncology.

## POTENTIAL APPLICATIONS

- Development of antitumour therapies directed to EGFR.
- Vehicle for radioisotopes or chemotherapeutic treatments against the tumours.
- Image-based tumour diagnosis by combination with fluorescent agents.

## ROADMAP / TIME-TO-MARKET

- Projects R+D Challenge Programs 2019 (RTI2018-100709-B-C22)
- The researchers are interested in technology transfer to a third party and in improving its development in cooperation with an external company.

### RESEARCH GROUP

Targeted Antitumour  
Therapies Research  
Group

Theoretical Chemistry  
of Biosystems  
Research Group  
(TCBioSys)

University of Girona  
(UdG)

TRL – 4

### CONTACT

Unitat d'Innovació i  
Transferència de l'RDl

Oficina Tècnica de  
Recerca i  
Transferència (OTRiT)

–  
UdG

transferencia@udg.edu  
+34 972 41 81 47